Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 12Active not recruiting 5Withdrawn 1Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 23Breast 17Gastrointestinal 10Endocrine 10CNS 10Lymphoid 8Head & Neck 8NET 7Tumor-Agnostic 6Thoracic 5Other hematologic neoplasm 3Dermatologic 3Sarcoma 2Plasma cell 2Other 1Myeloid 1Gynecologic 1Classical hematology 1

Conditions

Ovarian Neoplasms 1Neoplasms 1Colonic Neoplasms 1

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Everolimus × Gynecologic × Clear all
NCT01149434 2014-10-06

Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers

University of Utah

Phase 1/2 Terminated
19 enrolled 11 charts
GastrointestinalGynecologic

Colonic Neoplasms, Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡